Category Archives: Transhuman News

1-33 - I AM the-one-and-only ILLUMINATI
I AM the-one-and-only ILLUMINATI. There is none other than MY OWN SELF. Ocean of Heart You may view my art at: http://www.wix.com ILLUMINATI DOOMSDAY 2012 CONSCIOUSNESS AWARENESS WORLD HOPE HAPPINESS HAPPY PEACE NEW AGE TRUTH YOU ME I GOD CREATOR PRIME FORCE RENEWAL SACRED SECRET "secret society" REIGN SUN SON "second coming" SOLUTION PROBLEM DARKNESS LIGHT EARTH NATIVE FOREIGN ALIEN "alien invasion" CONSPIRACY SUCCESS MONEY "monetary system" "matej anzin" MATEJ ANZIN PERSON JUDAISM JEW HITLER SWASTIKA SYMBOL BALANCE HARMONY POSITIVE NEGATIVE MASCULINE FEMININE KUNDALINI DNA GENOME Ancient Spirit Energy UniverseFrom:OceanOfHeartViews:11 1ratingsTime:14:24More inEducation

Here is the original post:
1-33 - I AM the-one-and-only ILLUMINATI - Video

inFocus: Brian Weiner
Brian Weiner appreciates the collaborative nature of the Broad Institute #39;s work environment, having been inspired to pursue science after a collaboration between his high school teachers and a local drug company took him behind the scenes of a research lab. He #39;s now an associate computational biologist at the Broad, where he studies the genome sequences of viruses, combing the deluge of data for clues about how these viruses are evolving. The research that his group is conducting may lead to a better understanding of viral drug resistance and more effective treatments for infections. Learn more about Brian Weiner #39;s research and working at the Broad Institute: Genome Sequencing and Analysis Program (www.broadinstitute.org Viral Genomics Group (www.broadinstitute.org Human Immunodeficiency Virus (HIV) Portal (www.broadinstitute.org Careers at the Broad Institute (www.broadinstitute.orgFrom:broadinstituteViews:1 0ratingsTime:04:42More inScience Technology

See original here:
inFocus: Brian Weiner - Video

The Human Genome
Date: 07 05 2010 To access the full archive and all the latest daily shows please visit and subscribe to this channel: http://www.youtube.com IF you would like to be notified the minute the daily show is released each day why not subscribe here http://www.youtube.com Also please subscribe on TWITTER heres the address or just click the twitter link on the right of the channel page twitter.com FACEBOOK heres the address or just click the facebook link on the right of the channel page http://www.facebook.comFrom:ConspiracyHubViews:0 0ratingsTime:02:32:21More inNews Politics

Continue reading here:
The Human Genome - Video

GGN: Brazilian Tribe Threatens Mass Suicide, Student Kicked Out for Bad Genes, DNA Hacking Drones?
PLEASE DONATE Visit http://www.ggnonline.com to make a PayPal donation because it would be greatly appreciated. Thank you. -Darko PLEASE SUBSCRIBE Please visit http://www.ggnonline.com or http for the latest news commentary by Global Government News HEADLINES WITH LINKS: We will commit mass suicide if evicted from our homeland, Guarani-Kaiowa say bit.ly Switzerland biggest bank UBS AG to cut up to 10000 jobs: Source bit.ly China #39;s Gambit: Renminbi on the International Stage bit.ly EU, US to negotiate free-trade deal from spring 2013: officials reut.rs UK to export #39;nudge unit #39; (Behavior Modification) to Australia bit.ly Early Aussie Immigration Propaganda Poster bit.ly Australia Pushes Foreign Langauge to prepare the nation for the "Asian Century" bit.ly World Health Organisation #39;taking cash handouts from Coca-Cola to plug black holes in budget #39; bit.ly Ontario doctors target junk food with grisly cigarette-like warning labels bit.ly Autism Linked to High-Fructose Corn Syrupv bit.ly #39;Don #39;t f**g drink drive! #39;: Hard hitting ad campaign against drunk drivers in Russia bit.ly Doctors Call Tobacco Industry Terrorist Movement bit.ly Marlboro Maker Targets China #39;s Vaccine Market bit.ly Breaking News: Gardasil Fingerprints Found in Post-Mortem Samples bit.ly Switzerland, Italy Ban Novartis Flu Vaccines on.wsj.com GM Wheat May Permanently Alter Human Genome, Spark Early Death bit.ly School Kicks Out Boy for Having Cystic Fibrosis Gene bit.ly Pre-pregnancy genetic screening backed by ...From:DDarko2013Views:7 1ratingsTime:15:01More inNews Politics

Here is the original post:
GGN: Brazilian Tribe Threatens Mass Suicide, Student Kicked Out for Bad Genes, DNA Hacking Drones? - Video

RICHARD DAWKINS: Sex, Death And The Meaning Of Life, Episode 2. [HD] 720p
In the second episode of the three part series, Richard Dawkins tries to understand how the relationship between death and religion has evolved to be so strong, searching for answers for the questions such as "what makes us unique?", "why did not natural selection favor longevity genes?" from an evolutionary perspective. He visits his own mother, Jean Dawkins and family vault and meets James Vatson, co-discoverer of the structure of DNA. For the first time, he got his entire genome decoded to reveal what makes he live and how and when he might die.From:Nacido AteoViews:1 1ratingsTime:47:07More inEducation

Go here to see the original:
RICHARD DAWKINS: Sex, Death And The Meaning Of Life, Episode 2. [HD] 720p - Video

Dr. Alex Meissner -- Advances in Stem Cell Research
Learn more at http://www.invitrogen.com Dr. Alex Meissner, Assistant Professor at the Department of Stem Cell and Regenerative Biology at Harvard University, discusses how next generation sequencing has revolutionized the way we look at stem cells and perform stem cell research. Dr. Meissner talks about the challenges of interpreting genome wide data to provide stem cells with the right cues for efficient proliferation and differentiation and how the resulting cell models can be used to improve compound screening and cell therapy research applications.From:LifeTechnologiesCorpViews:0 0ratingsTime:02:56More inEducation

Here is the original post:
Dr. Alex Meissner -- Advances in Stem Cell Research - Video

The Joy Genome: Week 1
From:EchoNormanViews:0 0ratingsTime:37:43More inPeople Blogs

Read the original:
The Joy Genome: Week 1 - Video

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 13/457,041 (the 041 Application). The allowed claims relate to materials and substitutions used for the creation of enzymes capable of modifying endogenous locations within a complex genome. These materials and substitutions constitute an important aspect of Precisions genome engineering technologies, known collectively as the Directed Nuclease Editor or DNE.

Precisions DNE technology allows for highly precise gene editing with engineered nucleases, a technique named Method of the Year by Nature Methods. The Notice of Allowance will further augment Precisions ability to protect and capitalize on this important biological tool. Upon issuance of the 041 Application, Precision will control a patent estate consisting of eleven foundational genome engineering patents in the U.S. and one in Europe. The 041 Application is expected to issue as U.S. Patent No. 8,304,222 on November 6, 2012.

We are pleased that the U.S. Patent Office continues to recognize our novel contributions to the genome engineering field, stated Derek Jantz, co-inventor and Precision BioSciences Vice President of Scientific Development. This patent will allow us to protect yet another valuable aspect of our nuclease technology.

About Precision BioSciences

Precision BioSciences mission is to continually provide, improve, and enable the worlds most powerful genome engineering technology. Precisions proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences vision is to be the conduit through which the worlds greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the worlds largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit http://www.precisionbiosciences.com.

Go here to see the original:
Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases

The blood tests may herald a new wave of noninvasive prenatal screening.

Expectant mothers are used to fuzzy images on ultrasound monitors and blood tests to screen for potential health problems in their unborn babies. But what if one of those blood tests came back with a readout of the baby's entire genome? What if a simple test gave parents every nuance of a baby's genetic makeup before birth?

Recent studies show that it's possible to decode an entire fetal genome from a sample of the mother's blood (see "Using Parents' Blood to Decode the Genome of a Fetus"). In the future, doctors may be able to divine a wealth of information about genetic diseases or other characteristics of a fetus from the pregnant mother's blood. Such tests will raise ethical questions about how to act on such information. But they could also lead to research on treating diseases before birth, and leave parents and their doctors better prepared to care for babies after birth.

It's been about 15 years since Dennis Lo, a chemical pathologist at the Chinese University of Hong Kong, first discovered that fragments of DNA from a fetus could be found in a pregnant woman's blood. The work was a breakthrough, since obtaining fetal DNA from the amniotic fluid, placenta, or directly from the fetus's blood requires an invasive procedure and carries a risk of miscarriage. A noninvasive test would make genetic testing safer and much more widely accessible.

Since then, several labs have worked to analyze this fetal DNA and exploit it for noninvasive prenatal tests. The field has progressed rapidly in the past couple of years as genetic sequencing technologies have become vastly cheaper and faster, and methods to analyze genetic data have improved (see "Analyzing the Unborn Genome").

One of the first tests to be developed is for RhD factor, a type of blood protein that can lead to fetal disease or death if the mother is RhD negative and her fetus is RhD positive. Sequenom, a San Diego, California-based company that licensed Lo's research, began offering a noninvasive RhD test in 2010 (prior tests required invasive procedures such as amniocentesis or chorionic villus sampling, which carry a small risk of miscarriage). Several companies have also offered tests for sex determination and paternity.

But what has gained more attention in the United States is a recent wave of tests that detect Down syndrome, which is caused by an extra copy of chromosome 21. Because women in the United States are routinely offered testing for Down syndrome, the market for such a test is large.

The test for Down syndrome could, in particular, have an enormous beneficial impact. Typically, a pregnant woman receives an initial screening test for substances in her blood associated with Down syndrome. Jacob Canick, a professor of pathology and laboratory medicine at Brown University, explains that the tests will detect 90 percent of Down syndrome cases, but have a false positive rate of 2 to 5 percent. That may sound small, but given that Down syndrome affects only one in 500 pregnancies, the number of women with a false positive is much higher than those who are truly carrying an affected fetus. The only definitive diagnosis is through amniocentesis or chorionic villus sampling. "That means that 19 out of 20 women that undergo an invasive procedure will find out that they don't have the genetic abnormality," Canick says.

With those low odds, many women choose not to undergo an invasive procedure at all. But new noninvasive tests could make screening much more widespread. "It looks, from our data and other data, that these tests are very, very good," says Canick, who led a trial, funded by Sequenom, on one these tests. They are still not definitive, but could ensure that far fewer women unnecessarily undergo invasive tests.

A number of startups have begun offering fetal tests for Down syndrome and other health problems caused by extra copies or missing chromosomes. Diana Bianchi, executive director of the Mother Infant Research Institute at Tufts Medical Center, who is on the advisory board of a startup called Verinata Health that is developing such fetal tests, says it's been surprising how quickly the tests have made their way into the clinic.

Continue reading here:
New Tests Could Divine a Baby's Genome Before Birth

Public release date: 24-Oct-2012 [ | E-mail | Share ]

Contact: Glenna Picton picton@bcm.edu 713-798-4710 Baylor College of Medicine

HOUSTON -- (October 24, 2012) , said a Baylor College of Medicine physician-scientist who was part of the local team that took part in the international effort. A report appears online in the journal Nature.

"We now know every gene involved in pancreatic cancer," said Dr. William Fisher, professor of surgery and director of the Elkins Pancreas Center at BCM. "This study ushers in a whole new era of taking care of patients with pancreatic cancer. We will look back on this as a turning point in understanding and treating this disease."

The study follows a five-year collaboration between the Michael E. DeBakey Department of Surgery and the Baylor College of Medicine Human Genome Sequencing Center, said Fisher.

The Baylor College of Medicine Human Genome Sequencing Center was one of three sequencing centers worldwide that analyzed the genomes of pancreatic tumors and normal tissues taken from 142 patients with the disease. The BCM center, along with the Australian Pancreatic Center Genome Initiative and the Ontario Institute for Cancer Research Pancreatic Cancer Genome Study carried out detailed studies on 99 of the tumors, identifying 1982 mutations that resulted in a change to a protein and 1,628 significant copy number variations events in which the structure of the chromosomes themselves are changed, either deleting or duplicating genetic information.

The multi-institution, international consortium of researchers discovered mutations in genes involved in chromatin modification (changes that affect the way DNA is packaged inside the cell) and axon guidance (the process by which the axon a long threadlike project that carries impulses away from the neuron is guided to grow to its proper target).

"This is a category of genes not previously linked to pancreatic cancer," said Fisher. "We are poised to jump on this gene list and do some exciting things."

New information is much welcome in the field of pancreatic cancer, which is the fourth leading cause of cancer death with an overall five-year survival rate of less than 5 percent. The figures have not changed substantially in the past 50 years.

The study is the first to report findings from primary tumors in the disease. Previously only cell lines or tumors transplanted into mice had been used because the tumors are so small. "Therefore it required new techniques to sensitively identify mutations that were important to the development of cancer," said Dr. David Wheeler, associate professor in the BCM Human Genome Sequencing Center who oversees the center's cancer projects. Wheeler and Fisher are also members of the NCI-designated Dan L. Duncan Cancer Center at BCM.

Here is the original post:
Genome analysis of pancreas tumors reveals new pathway